Resumen
Accurate interpretation of genomic copy number variation (CNV) remains a challenge and has important consequences for both congenital and late-onset disease. Hemizygosity dosage characterization of the genes on chromosome 18 reveals a spectrum of outcomes ranging from no clinical effect, to risk factors for disease, to both low- and high-penetrance disease. These data are important for accurate and predictive clinical management. Additionally, the potential mechanisms of reduced penetrance due to dosage compensation are discussed as a key to understanding avenues for potential treatment. This review describes the chromosome 18 findings, and discusses the molecular mechanisms that allow haploinsufficiency, reduced penetrance, and dosage compensation.
Idioma original | English (US) |
---|---|
Páginas (desde-hasta) | 764-776 |
Número de páginas | 13 |
Publicación | Trends in Genetics |
Volumen | 36 |
N.º | 10 |
DOI | |
Estado | Published - oct 2020 |
ASJC Scopus subject areas
- Genetics